Abstract
Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
CNS & Neurological Disorders - Drug Targets
Title: Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
Volume: 10 Issue: 3
Author(s): Anne Penttinen, Jofre Tenorio-Laranga, Anssi Siikanen, Markus Morawski, Steffen Roßner and J. Arturo Garcia-Horsman
Affiliation:
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
Abstract: Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Export Options
About this article
Cite this article as:
Penttinen Anne, Tenorio-Laranga Jofre, Siikanen Anssi, Morawski Markus, Roßner Steffen and Arturo Garcia-Horsman J., Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653742
DOI https://dx.doi.org/10.2174/187152711794653742 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contrast Medium Induced Nephropathy: New Insights into Prevention and Risk Management
Cardiovascular & Hematological Agents in Medicinal Chemistry Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Recent Applications of Doebner, Doebner-von Miller and Knoevenagel-Doebner Reactions in Organic Syntheses
Current Organic Synthesis Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Critical Roles for Bradykinin and Prostanoids in Acute Inflammatory Reactions: A Search Using Experimental Animal Models
Current Drug Targets - Inflammation & Allergy The Burden of Metabolic Diseases Amongst HIV Positive Patients on HAART Attending the Johannesburg Hospital
Current HIV Research From the Stretcher to the Pharmacys Shelf: Drug Leads from Medically Important Brazilian Venomous Arachnid Species
Inflammation & Allergy - Drug Targets (Discontinued) Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Quick-Release Bromocriptine for Treatment of Type 2 Diabetes
Current Drug Delivery Anti-hypertensive Effects of Diminazene Aceturate: An Angiotensin- Converting Enzyme 2 Activator in Rats
Protein & Peptide Letters Molecular Determinants of Fluoroquinolone Antibacterial Agents Pharmacokinetics
Current Clinical Pharmacology Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Dopamine and Vascular Dynamics Control: Present Status and Future Perspectives
Current Neurovascular Research Chemical Constituents of Plants from the Genus Valeriana
Mini-Reviews in Organic Chemistry Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients
Infectious Disorders - Drug Targets Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews